Relpax is a drug owned by Upjohn Manufacturing Ireland Unltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 29, 2017. Details of Relpax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6110940 | Salts of an anti-migraine indole derivative |
Aug, 2017
(7 years ago) |
Expired
|
| US5545644 | Indole derivatives |
Dec, 2016
(7 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Relpax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Relpax's family patents as well as insights into ongoing legal events on those patents.
Relpax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Relpax's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 29, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Relpax Generic API suppliers:
Eletriptan Hydrobromide is the generic name for the brand Relpax. 8 different companies have already filed for the generic of Relpax, with Ajanta Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Relpax's generic
How can I launch a generic of Relpax before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Relpax's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Relpax's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Relpax -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 20 mg and 40 mg | 29 Mar, 2010 | 1 | 29 Aug, 2017 | Extinguished |
About Relpax
Relpax is a drug owned by Upjohn Manufacturing Ireland Unltd. It is used for treating migraines with or without aura. Relpax uses Eletriptan Hydrobromide as an active ingredient. Relpax was launched by Upjohn in 2002.
Approval Date:
Relpax was approved by FDA for market use on 26 December, 2002.
Active Ingredient:
Relpax uses Eletriptan Hydrobromide as the active ingredient. Check out other Drugs and Companies using Eletriptan Hydrobromide ingredient
Treatment:
Relpax is used for treating migraines with or without aura.
Dosage:
Relpax is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | TABLET | Prescription | ORAL |
| EQ 20MG BASE | TABLET | Prescription | ORAL |